In a regulatory filing, Connect Biopharma (CNTB) disclosed that its director James Huang bought 1.16M shares of common stock on March 31 in a total transaction size of $4.0M. Shares are up 6.6% afterhours.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTB:
- Buy Rating on CNTB Driven by Rademikibart’s Rapid Lung Function Gains, COPD Differentiation, and Strengthened Cash Runway
- Buy Rating on CNTB: Fast-Acting Rademikibart Data Underscore Differentiation and Long-Term Respiratory Opportunity
- Connect Biopharma Highlights Positive Rademikibart Respiratory Trial Results
- Connect Biopharma announces results from rademikibart study
- CNTB Earnings Report this Week: Is It a Buy, Ahead of Earnings?